BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...neuroendocrine tumor drug Lutathera. A year later, Novartis acquired Endocyte Inc. for $2.1 billion, obtaining 177Lu-PSMA-617...
...III testing for PSMA-positive metastatic CRPC due to read out in 2020. Endocyte had bought 177Lu-PSMA-617...
BioCentury | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

...Novartis. While the company’s current programs are built around emitters of beta radiation, such as 177Lu-PSMA-617...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...the pharma “sees the power of linking a radioactive particle to a well-described ligand.” Endocyte’s 177Lu-PSMA-617...
...Brolucizumab Next-generation single-chain anti-vascular endothelial growth factor (VEGF) antibody fragment Wet age-related macular degeneration Registration 177Lu-PSMA-617...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...Inc. (NYSE:ABBV) is in Phase III testing for both indications. Novartis AG (NYSE:NVS; SIX:NOVN) gained 177Lu-PSMA-617...
...Veliparib Ph II Zytiga Zytiga monotherapy PSMA inhibitors ABX GmbH / Novartis AG (NYSE:NVS; SIX:NOVN) 177Lu-PSMA-617...
...in the clinic, the small molecule radioligand 177Lu-PSMA-617 is the most advanced. Novartis AG gained 177Lu-PSMA-617...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...tumor antigens in animal models of TNBC. ABX GmbH, Endocyte Inc. and RadioMedix Inc. have 177Lu-PSMA-617...
BioCentury | Oct 19, 2018
Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

...cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617...
...rPFS as an efficacy endpoint to support an NDA submission. Novartis also plans to evaluate 177Lu-PSMA-617...
...Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Endocyte Inc. (NASDAQ:ECYT), West Lafayette, Ind. Business: Cancer Jennie Walters 177Lu-PSMA-617, Lu177-PSMA-617 Ilaris...
BioCentury | Oct 18, 2018
Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

...cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617...
...rPFS as an efficacy endpoint to support an NDA submission. Novartis also plans to evaluate 177Lu-PSMA-617...
...billion. Endocyte gained $7.84 (50%) to $23.40 on Thursday. Consensus figures provided by FactSet. Jennie Walters 177Lu-PSMA-617, Lu177-PSMA-617 Endocyte...
BioCentury | Sep 13, 2018
Company News

Endocyte raises $175M

...rose 11% Sept. 10 after the company said FDA clarified the regulatory path for its 177Lu-PSMA-617...
...before full OS data are mature, although Endocyte would still conduct a full OS assessment. 177Lu-PSMA-617...
...non-metastatic patients. Johnson & Johnson (NYSE:JNJ) markets Zytiga. Endocyte Inc. (NASDAQ:ECYT), West Lafayette, Ind. Paul Bonanos 177Lu-PSMA-617, Lu177-PSMA-617 Zytiga...
BioCentury | Sep 12, 2018
Financial News

With clear regulatory path, Endocyte raises $175M

...rose 11% on Monday after the company said FDA clarified the regulatory path for its 177Lu-PSMA-617...
...before full OS data are mature, although Endocyte would still conduct a full OS assessment. 177Lu-PSMA-617...
...treat cRPC in both metastatic and non-metastatic patients. Johnson & Johnson (NYSE:JNJ) markets Zytiga. Paul Bonanos 177Lu-PSMA-617, Lu177-PSMA-617 Endocyte...
BioCentury | May 18, 2018
Clinical News

Endocyte's radioligand therapy reduces PSA in CRPC patients

...Newly released data showed that 177Lu-PSMA-617 from Endocyte Inc. (NASDAQ:ECYT) reduced prostate-specific antigen (PSA; KLK3) levels...
...in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. 177Lu-PSMA-617...
...PFS) and overall survival (OS) Status: Phase II data Milestone: Start Phase III (2Q18) Chris Lieu 177Lu-PSMA-617, Lu177-PSMA-617 ABX...
Items per page:
1 - 10 of 14